DOCSLIB.ORG

The Four Cysteine Residues in the Second Extracellular Loop of the Human Adenosine a Receptor: Role in Ligand Binding and Receptor Function Anke C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Four Cysteine Residues in the Second Extracellular Loop of the Human Adenosine a Receptor: Role in Ligand Binding and Receptor Function Anke C The four cysteine residues in the second extracellular loop of the human adenosine A receptor: role in ligand binding and receptor function Anke C. Schiedel, Sonja Hinz, Dominik Thimm, Farag Sherbiny, Thomas Borrmann, Astrid Maaß, Christa E. Müller To cite this version: Anke C. Schiedel, Sonja Hinz, Dominik Thimm, Farag Sherbiny, Thomas Borrmann, et al.. The four cysteine residues in the second extracellular loop of the human adenosine A receptor: role in ligand binding and receptor function. Biochemical Pharmacology, Elsevier, 2011, 82 (4), pp.389. 10.1016/j.bcp.2011.05.008. hal-00718035 HAL Id: hal-00718035 https://hal.archives-ouvertes.fr/hal-00718035 Submitted on 16 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function Authors: Anke C. Schiedel, Sonja Hinz, Dominik Thimm, Farag Sherbiny, Thomas Borrmann, Astrid Maaß, Christa E. Muller¨ PII: S0006-2952(11)00301-7 DOI: doi:10.1016/j.bcp.2011.05.008 Reference: BCP 10900 To appear in: BCP Received date: 18-2-2011 Revised date: 9-5-2011 Accepted date: 11-5-2011 Please cite this article as: Schiedel AC, Hinz S, Thimm D, Sherbiny F, Borrmann T, Maaß A, Muller¨ CE, The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function, Biochemical Pharmacology (2010), doi:10.1016/j.bcp.2011.05.008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1 2 3 4 The four cysteine residues in the second extracellular loop of the human 5 6 7 adenosine A2B receptor: role in ligand binding and receptor function 8 9 10 11 a, a a b 12 Anke C. Schiedel *, Sonja Hinz , Dominik Thimm , Farag Sherbiny , Thomas 13 a b a 14 Borrmann , Astrid Maaß , and Christa E. Müller 15 16 17 18 a 19 PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University 20 21 of Bonn, An der Immenburg 4, D-53121 Bonn, Germany 22 23 b 24 Fraunhofer Institute SCAI, Schloss Birlinghoven, 53754 Sankt Augustin, Germany 25 26 *corresponding author: [email protected], phone ++49 (228) 736457; fax ++49 27 28 29 (228) 732567; An der Immenburg 4, D-53121 Bonn, Germany 30 31 [email protected], [email protected], [email protected], 32 33 [email protected] , [email protected], 34 35 36 [email protected] 37 38 39 40 41 category: (5) Inflammation and Immunopharmacology 42 43 44 45 46 47 48 49 50 Accepted Manuscript 51 52 53 54 55 56 57 58 59 60 61 62 1 63 64 Page 1 of 56 65 1 2 3 4 Abstract 5 6 7 8 9 The adenosine A2B receptor is of considerable interest as a new drug target for the 10 11 12 treatment of asthma, inflammatory diseases, pain, and cancer. In the present study we 13 14 investigated the role of the cysteine residues in the extracellular loop 2 (ECL2) of the 15 16 receptor, which is particularly cysteine-rich, by a combination of mutagenesis, molecular 17 18 19 modeling, chemical and pharmacological experiments. Pretreatment of CHO cells 20 21 recombinantly expressing the human A2B receptor with dithiothreitol led to a 74-fold 22 23 24 increase in the EC50 value of the agonist NECA in cyclic AMP accumulation. In the 25 3.25 45.50 26 C78 S and the C171 S mutants high-affinity binding of the A2B antagonist 27 28 3 29 radioligand [ H]PSB-603 was abolished and agonists were virtually inactive in cAMP 30 31 assays. This indicates that the C3.25-C45.50 disulfide bond, which is highly conserved 32 33 in GPCRs, is also important for binding and function of A receptors. In contrast, the 34 2B 35 45.45 45.46 45.45 45.46 36 C166 S and the C167 S mutants as well as the C166 S-C167 S double 37 38 mutant behaved like the wild-type receptor, while in the C15445.33S mutant significant, 39 40 41 although more subtle effects on cAMP accumulation were observed - decrease (BAY60- 42 43 6583) or increase (NECA) - depending on the structure of the investigated agonist. In 44 45 46 contrast to the X-ray structure of the closely related A2A receptor, which showed four 47 48 disulfide bonds, the present data indicate that in the A2B receptor only the C3.25-C45.50 49 Accepted Manuscript 50 disulfide bond is essential for ligand binding and receptor activation. Thus, the cysteine 51 52 53 residues in the ECL2 of the A2B receptor not involved in stabilization of the receptor 54 55 structure may have other functions. 56 57 58 59 60 Keywords 61 62 2 63 64 Page 2 of 56 65 1 2 3 4 5 6 7 Adenosine A2B receptor; disulfide bonds; extracellular loop 2; mutagenesis; PSB-603 8 9 10 11 12 1 Introduction 13 14 15 16 Adenosine A receptors belong to the large group of purinergic G protein-coupled 17 2B 18 19 receptors (GPCRs), which comprise P2 (P2Y and P2X, nucleotide-activated ) and P1 20 21 (adenosine) receptors [1]. Brunschweiger and Müller [2] proposed to add P0 (adenine) 22 23 24 receptors as a third class to the group of purinergic receptors. The P1 or adenosine 25 26 receptor (AR) family consists of four subtypes, A1, A2A, A2B and A3 [3]. A1 and A3 27 28 29 receptors are coupled to Gi type G proteins, leading to the inhibition of the adenylate 30 31 cyclase upon receptor activation, while A2A and A2B receptors are mainly coupled to Gs 32 33 proteins resulting in an increase in intracellular cAMP concentrations via stimulation of 34 35 36 adenylate cyclase [4]. In several cell systems, such as HEK-293 and HMC-1 mast cells 37 38 A2B receptors are additionally coupled to phospholipase C via Gq proteins, and are 39 40 2+ 41 thereby linked to intracellular Ca release [5-6]. In the human leukemia cell line Jurkat 42 43 T, A2B-mediated calcium mobilization independent of inositol-1,4,5-trisphosphate was 44 45 46 observed [7]. Coupling of the A2B receptor to the MAPK cascade via ERK1/2 has been 47 48 described for recombinant CHO cells overexpressing human A2B receptors and for mast 49 Accepted Manuscript 50 cells, showing an involvement in proliferation, differentiation and apoptosis [4, 8]. 51 52 53 Furthermore a link of A2B receptor signaling to the arachidonic acid signal transduction 54 55 pathway via phospholipase A and cyclooxygenase activation leading to vasoconstriction 56 57 58 in smooth muscle cells has been described [9]. 59 60 61 62 3 63 64 Page 3 of 56 65 1 2 3 4 Among the four AR subtypes A2B has been the least well characterized receptor, mainly 5 6 7 due to the lack of suitable, specific ligands [10]. Meanwhile highly selective A2B 8 3 9 antagonists have been developed and an A2B-specific antagonist radioligand, [ H]PSB- 10 11 12 603 (for structure see figure 1), with high potency and specificity across species, 13 14 including rodents and humans, has recently become available [11]. As for agonists, 15 16 besides the nucleoside derivative NECA [12], which is non-selective, and related 17 18 19 adenosine derivatives, the first highly selective A2B agonist BAY60-6583 [13], a non- 20 21 nucleosidic compound, has been developed (structures are shown in supplemental 22 23 24 figure 1). 25 26 In many tissues, A2B receptors are considered low affinity receptors with typically low 27 28 29 expression levels [14]. Therefore, adenosine concentrations typically have to reach 30 31 micromolecular levels to activate natively expressed A2B receptors, which occurs under 32 33 pathological conditions, such as hypoxia, ischemia, inflammation or massive cell death 34 35 36 [15-16]. While their distribution is ubiquitous, A2B receptors are found at higher densities 37 38 mainly in the large intestine, in mast cells, hematopoietic cells, and in the brain, mainly 39 40 41 in astrocytes [6, 14, 17-18]. Upregulation has been found in several cancer cell lines 42 43 [19]. A2B receptors are thought to be involved in a number of diseases and the first 44 45 46 antagonist is now being evaluated in clinical trials for the treatment of asthma and 47 48 chronic obstructive pulmonary disease [10]. Other potential indications include secretory 49 Accepted Manuscript 50 diarrhea associated with inflammation, Alzheimer’s disease, inflammatory diseases, 51 52 53 pain, cancer, type II diabetes, and diabetic retinopathy [20]. Thus, A2B receptors 54 55 represent important new drug targets. 56 57 58 To fully understand interactions of the human A2B receptor with its ligands, agonists and 59 60 antagonists, it is of major importance to gain knowledge about the structure of the 61 62 4 63 64 Page 4 of 56 65 1 2 3 4 receptor, the amino acid residues involved in ligand binding, and to determine the 5 6 7 receptor's 3D structure, which in turn can then be used for the development of new 8 9 ligands [21-22].
Load more

Recommended publications
  • Molecular Dissection of G-Protein Coupled Receptor Signaling and Oligomerization
    MOLECULAR DISSECTION OF G-PROTEIN COUPLED RECEPTOR SIGNALING AND OLIGOMERIZATION BY MICHAEL RIZZO A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Biology December, 2019 Winston-Salem, North Carolina Approved By: Erik C. Johnson, Ph.D. Advisor Wayne E. Pratt, Ph.D. Chair Pat C. Lord, Ph.D. Gloria K. Muday, Ph.D. Ke Zhang, Ph.D. ACKNOWLEDGEMENTS I would first like to thank my advisor, Dr. Erik Johnson, for his support, expertise, and leadership during my time in his lab. Without him, the work herein would not be possible. I would also like to thank the members of my committee, Dr. Gloria Muday, Dr. Ke Zhang, Dr. Wayne Pratt, and Dr. Pat Lord, for their guidance and advice that helped improve the quality of the research presented here. I would also like to thank members of the Johnson lab, both past and present, for being valuable colleagues and friends. I would especially like to thank Dr. Jason Braco, Dr. Jon Fisher, Dr. Jake Saunders, and Becky Perry, all of whom spent a great deal of time offering me advice, proofreading grants and manuscripts, and overall supporting me through the ups and downs of the research process. Finally, I would like to thank my family, both for instilling in me a passion for knowledge and education, and for their continued support. In particular, I would like to thank my wife Emerald – I am forever indebted to you for your support throughout this process, and I will never forget the sacrifices you made to help me get to where I am today.
    [Show full text]
  • A2B Adenosine Receptors and T Cell Activation 493
    Journal of Cell Science 112, 491-502 (1999) 491 Printed in Great Britain © The Company of Biologists Limited 1999 JCS0069 Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation Maribel Mirabet1, Carolina Herrera1, Oscar J. Cordero2, Josefa Mallol1, Carmen Lluis1 and Rafael Franco1,* 1Department of Biochemistry and Molecular Biology, Faculty of Chemistry, University of Barcelona, Barcelona, Catalonia, Spain 2Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Santiago de Compostela, Spain *Author for correspondence (e-mail: [email protected]; homepage: www.bq.ub.es/recep/franco.html) Accepted 9 December 1998; published on WWW 25 January 1999 SUMMARY Extracellular adenosine has a key role in the development A2BRs but not of A2A receptors in these human cells. The and function of the cells of the immune system. Many of percentage of A2BR-expressing cells was similar in the the adenosine actions seem to be mediated by specific CD4+ or CD8+ T cell subpopulations. Interestingly surface receptors positively coupled to adenylate cyclase: activation signals delivered by either phytohemagglutinin A2A and A2B. Despite the fact that A2A receptors (A2ARs) or anti-T cell receptor/CD3 complex antibodies led to a can be easily studied due to the availability of the specific significant increase in both the percentage of cells agonist CGS21680, a pharmacological and physiological expressing the receptor and the intensity of the labeling. characterization of adenosine A2B receptors (A2BRs) in These receptors are functional since interleukin-2 lymphocytes has not been possible due to the lack of production in these cells is reduced by NECA but not by R- suitable reagents.
    [Show full text]
  • MTAP Loss Correlates with an Immunosuppressive Profile in GBM and Its Substrate MTA Stimulates Alternative Macrophage Polarization
    bioRxiv preprint doi: https://doi.org/10.1101/329664; this version posted May 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization Landon J. Hansen1,2,3, Rui Yang1,2, Karolina Woroniecka1,2, Lee Chen1,2, Hai Yan1,2, Yiping He 1,2,* From the 1The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA; 2Department of Pathology, Duke University Medical Center, Durham, NC, USA; 3Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA; 4Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA *Corresponding Author: Yiping He, PhD, 203 Research Drive, Medical Science Research Building 1, Room 199A Durham, NC, USA 27710 Phone: (919) 684-4760 E-mail: [email protected] Keywords: MTAP, GBM, macrophages, M2, MTA, adenosine ABSTRACT INTRODUCTION Glioblastoma (GBM) is a lethal brain cancer known for Immunotherapy possesses enormous potential for treating its potent immunosuppressive effects. Loss of cancer and has reshaped the way we understand and treat Methylthioadenosine Phosphorylase (MTAP) expression, certain cancer types (1,2). Despite recent progress, via gene deletion or epigenetic silencing, is one of the however, the promise of immunotherapy-based most common alterations in GBM. Here, we show that approaches for treating brain tumors, in particular high MTAP loss in GBM cells is correlated with differential grade glioblastoma (GBM), remains to be fully realized expression of immune regulatory genes.
    [Show full text]
  • Specific Labeling of Synaptic Schwann Cells Reveals Unique Cellular And
    RESEARCH ARTICLE Specific labeling of synaptic schwann cells reveals unique cellular and molecular features Ryan Castro1,2,3, Thomas Taetzsch1,2, Sydney K Vaughan1,2, Kerilyn Godbe4, John Chappell4, Robert E Settlage5, Gregorio Valdez1,2,6* 1Department of Molecular Biology, Cellular Biology, and Biochemistry, Brown University, Providence, United States; 2Center for Translational Neuroscience, Robert J. and Nancy D. Carney Institute for Brain Science and Brown Institute for Translational Science, Brown University, Providence, United States; 3Neuroscience Graduate Program, Brown University, Providence, United States; 4Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, United States; 5Department of Advanced Research Computing, Virginia Tech, Blacksburg, United States; 6Department of Neurology, Warren Alpert Medical School of Brown University, Providence, United States Abstract Perisynaptic Schwann cells (PSCs) are specialized, non-myelinating, synaptic glia of the neuromuscular junction (NMJ), that participate in synapse development, function, maintenance, and repair. The study of PSCs has relied on an anatomy-based approach, as the identities of cell-specific PSC molecular markers have remained elusive. This limited approach has precluded our ability to isolate and genetically manipulate PSCs in a cell specific manner. We have identified neuron-glia antigen 2 (NG2) as a unique molecular marker of S100b+ PSCs in skeletal muscle. NG2 is expressed in Schwann cells already associated with the NMJ, indicating that it is a marker of differentiated PSCs. Using a newly generated transgenic mouse in which PSCs are specifically labeled, we show that PSCs have a unique molecular signature that includes genes known to play critical roles in *For correspondence: PSCs and synapses. These findings will serve as a springboard for revealing drivers of PSC [email protected] differentiation and function.
    [Show full text]
  • Adenosine Signaling and Function in Glial Cells
    Cell Death and Differentiation (2010) 17, 1071–1082 & 2010 Macmillan Publishers Limited All rights reserved 1350-9047/10 $32.00 www.nature.com/cdd Review Adenosine signaling and function in glial cells D Boison*,1, J-F Chen2 and BB Fredholm3 Despite major advances in a variety of neuroscientific research fields, the majority of neurodegenerative and neurological diseases are poorly controlled by currently available drugs, which are largely based on a neurocentric drug design. Research from the past 5 years has established a central role of glia to determine how neurons function and, consequently, glial dysfunction is implicated in almost every neurodegenerative and neurological disease. Glial cells are key regulators of the brain’s endogenous neuroprotectant and anticonvulsant adenosine. This review will summarize how glial cells contribute to adenosine homeostasis and how glial adenosine receptors affect glial function. We will then move on to discuss how glial cells interact with neurons and the vasculature, and outline new methods to study glial function. We will discuss how glial control of adenosine function affects neuronal cell death, and its implications for epilepsy, traumatic brain injury, ischemia, and Parkinson’s disease. Eventually, glial adenosine-modulating drug targets might be an attractive alternative for the treatment of neurodegenerative diseases. There are, however, several major open questions that remain to be tackled. Cell Death and Differentiation (2010) 17, 1071–1082; doi:10.1038/cdd.2009.131; published online 18 September 2009 It is becoming increasingly clear that inflammatory processes Glial Control of Adenosine Homeostasis play an important role in neurodegenerative disease, just as In mammals, purine de novo synthesis proceeds via formation inflammation is becoming increasingly implicated in various of IMP, which is then converted into AMP; however, there is no systemic diseases elsewhere in the body.1 As the immune de novo synthesis pathway for adenosine.
    [Show full text]
  • Adenosine, an Endogenous Distress Signal, Modulates Tissue Damage and Repair
    Cell Death and Differentiation (2007) 14, 1315–1323 & 2007 Nature Publishing Group All rights reserved 1350-9047/07 $30.00 www.nature.com/cdd Review Adenosine, an endogenous distress signal, modulates tissue damage and repair BB Fredholm*,1 Adenosine is formed inside cells or on their surface, mostly by breakdown of adenine nucleotides. The formation of adenosine increases in different conditions of stress and distress. Adenosine acts on four G-protein coupled receptors: two of them, A1 and A3, are primarily coupled to Gi family G proteins; and two of them, A2A and A2B, are mostly coupled to Gs like G proteins. These receptors are antagonized by xanthines including caffeine. Via these receptors it affects many cells and organs, usually having a cytoprotective function. Joel Linden1 recently grouped these protective effects into four general modes of action: increased oxygen supply/demand ratio, preconditioning, anti-inflammatory effects and stimulation of angiogenesis. This review will briefly summarize what is known and what is not in this regard. It is argued that drugs targeting adenosine receptors might be useful adjuncts in many therapeutic approaches. Cell Death and Differentiation (2007) 14, 1315–1323; doi:10.1038/sj.cdd.4402132; published online 30 March 2007 Adenosine Formation and Adenosine Levels out of the cells by means of efficient equilibrative transporters. There are inhibitors for these transporters, including the drug Adenosine is always present both within and outside cells, dipyridamole. These inhibitors will increase extracellular since it is at a crossroads between different metabolic adenosine if it derives from extracellular breakdown of pathways. Levels of adenosine in cells and tissue fluids is adenine nucleotides, but decrease it if adenosine is formed in the nanomolar range under physiological conditions intracellularly.
    [Show full text]
  • Oligodendrocytes Remodel the Genomic Fabrics of Functional Pathways in Astrocytes
    1 Article 2 Oligodendrocytes remodel the genomic fabrics of 3 functional pathways in astrocytes 4 Dumitru A Iacobas 1,2,*, Sanda Iacobas 3, Randy F Stout 4 and David C Spray 2,5 5 Supplementary Material 6 Table S1. Genes whose >1.5x absolute fold-change did not meet the individual CUT criterion. 7 Red/green background of the expression ratio indicates not significant (false) up-/down-regulation. Gene Description X CUT Acap2 ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 -1.540 1.816 Adamts18 a disintegrin-like and metallopeptidase -1.514 1.594 Akr1c12 aldo-keto reductase family 1, member C12 1.866 1.994 Alx3 aristaless-like homeobox 3 1.536 1.769 Alyref2 Aly/REF export factor 2 -1.880 2.208 Ankrd33b ankyrin repeat domain 33B 1.593 1.829 Ankrd45 ankyrin repeat domain 45 1.514 1.984 Ankrd50 ankyrin repeat domain 50 1.628 1.832 Ankrd61 ankyrin repeat domain 61 1.645 1.802 Arid1a AT rich interactive domain 1A -1.668 2.066 Artn artemin 1.524 1.732 Aspm abnormal spindle microtubule assembly -1.693 1.716 Atp6v1e1 ATPase, H+ transporting, lysosomal V1 subunit E1 -1.679 1.777 Bag4 BCL2-associated athanogene 4 1.723 1.914 Birc3 baculoviral IAP repeat-containing 3 -1.588 1.722 Ccdc104 coiled-coil domain containing 104 -1.819 2.130 Ccl2 chemokine -1.699 2.034 Cdc20b cell division cycle 20 homolog B 1.512 1.605 Cenpf centromere protein F 2.041 2.128 Cep97 centrosomal protein 97 -1.641 1.723 COX1 mitochondrially encoded cytochrome c oxidase I -1.607 1.650 Cpsf7 cleavage and polyadenylation specific factor 7 -1.635 1.891 Crct1 cysteine-rich
    [Show full text]
  • Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells Amy Sue Bogard University of Tennessee Health Science Center
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2013 Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells Amy Sue Bogard University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Medical Cell Biology Commons, and the Medical Molecular Biology Commons Recommended Citation Bogard, Amy Sue , "Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells" (2013). Theses and Dissertations (ETD). Paper 330. http://dx.doi.org/10.21007/etd.cghs.2013.0029. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Biomedical Sciences Track Molecular Therapeutics and Cell Signaling Research Advisor Rennolds Ostrom, Ph.D. Committee Elizabeth Fitzpatrick, Ph.D. Edwards Park, Ph.D. Steven Tavalin, Ph.D. Christopher Waters, Ph.D. DOI 10.21007/etd.cghs.2013.0029 Comments Six month embargo expired June 2014 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/330 Adenylyl Cyclase 2 Selectively Regulates IL-6 Expression in Human Bronchial Smooth Muscle Cells A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Amy Sue Bogard December 2013 Copyright © 2013 by Amy Sue Bogard.
    [Show full text]
  • Purinergic Signaling in the Hallmarks of Cancer
    cells Review Purinergic Signaling in the Hallmarks of Cancer Anaí del Rocío Campos-Contreras, Mauricio Díaz-Muñoz and Francisco G. Vázquez-Cuevas * Department of Cellular and Molecular Neurobiology, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla #3001, Juriquilla Querétaro 76230, Mexico; [email protected] (A.d.R.C.-C.); [email protected] (M.D.-M.) * Correspondence: [email protected]; Tel.: +52-(442)-238-1035 Received: 15 June 2020; Accepted: 2 July 2020; Published: 3 July 2020 Abstract: Cancer is a complex expression of an altered state of cellular differentiation associated with severe clinical repercussions. The effort to characterize this pathological entity to understand its underlying mechanisms and visualize potential therapeutic strategies has been constant. In this context, some cellular (enhanced duplication, immunological evasion), metabolic (aerobic glycolysis, failure in DNA repair mechanisms) and physiological (circadian disruption) parameters have been considered as cancer hallmarks. The list of these hallmarks has been growing in recent years, since it has been demonstrated that various physiological systems misfunction in well-characterized ways upon the onset and establishment of the carcinogenic process. This is the case with the purinergic system, a signaling pathway formed by nucleotides/nucleosides (mainly adenosine triphosphate (ATP), adenosine (ADO) and uridine triphosphate (UTP)) with their corresponding membrane receptors and defined transduction mechanisms. The dynamic equilibrium between ATP and ADO, which is accomplished by the presence and regulation of a set of ectonucleotidases, defines the pro-carcinogenic or anti-cancerous final outline in tumors and cancer cell lines. So far, the purinergic system has been recognized as a potential therapeutic target in cancerous and tumoral ailments.
    [Show full text]
  • Induction of Therapeutic Tissue Tolerance Foxp3 Expression Is
    Downloaded from http://www.jimmunol.org/ by guest on October 2, 2021 is online at: average * The Journal of Immunology , 13 of which you can access for free at: 2012; 189:3947-3956; Prepublished online 17 from submission to initial decision 4 weeks from acceptance to publication September 2012; doi: 10.4049/jimmunol.1200449 http://www.jimmunol.org/content/189/8/3947 Foxp3 Expression Is Required for the Induction of Therapeutic Tissue Tolerance Frederico S. Regateiro, Ye Chen, Adrian R. Kendal, Robert Hilbrands, Elizabeth Adams, Stephen P. Cobbold, Jianbo Ma, Kristian G. Andersen, Alexander G. Betz, Mindy Zhang, Shruti Madhiwalla, Bruce Roberts, Herman Waldmann, Kathleen F. Nolan and Duncan Howie J Immunol cites 35 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/09/17/jimmunol.120044 9.DC1 This article http://www.jimmunol.org/content/189/8/3947.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 2, 2021.
    [Show full text]
  • Correlated Motions of Conserved Polar Motifs Lay out a Plausible Mechanism of G Protein-Coupled Receptor Activation
    biomolecules Article Correlated Motions of Conserved Polar Motifs Lay out a Plausible Mechanism of G Protein-Coupled Receptor Activation Argha Mitra 1 , Arijit Sarkar 1 ,Márton Richárd Szabó 1,2 and Attila Borics 1,* 1 Laboratory of Chemical Biology, Institute of Biochemistry, Biological Research Centre, Szeged, 62. Temesvári krt., H-6726 Szeged, Hungary; [email protected] (A.M.); [email protected] (A.S.); [email protected] (M.R.S.) 2 Department of Biochemistry, Faculty of Medicine, University of Szeged, 9 Dóm sq., H-6720 Szeged, Hungary * Correspondence: [email protected]; Tel.: +36-62-599-600 (ext. 430) Abstract: Recent advancements in the field of experimental structural biology have provided high- resolution structures of active and inactive state G protein-coupled receptors (GPCRs), a highly important pharmaceutical target family, but the process of transition between these states is poorly understood. According to the current theory, GPCRs exist in structurally distinct, dynamically interconverting functional states of which populations are shifted upon binding of ligands and intracellular signaling proteins. However, explanation of the activation mechanism, on an entirely structural basis, gets complicated when multiple activation pathways and active receptor states are considered. Our unbiased, atomistic molecular dynamics simulations of the µ opioid receptor (MOP) revealed that transmission of external stimulus to the intracellular surface of the receptor is accompanied by subtle, concerted movements of highly conserved polar amino acid side chains along the 7th transmembrane helix. This may entail the rearrangement of polar species and the shift Citation: Mitra, A.; Sarkar, A.; Szabó, of macroscopic polarization in the transmembrane domain, triggered by agonist binding.
    [Show full text]
  • Insight of Captagon Abuse by Chemogenomics Knowledgebase
    www.nature.com/scientificreports OPEN Insight of Captagon Abuse by Chemogenomics Knowledgebase- guided Systems Pharmacology Received: 25 April 2018 Accepted: 10 September 2018 Target Mapping Analyses Published: xx xx xxxx Nan Wu1,2,3,4, Zhiwei Feng1,2,3,4, Xibing He1,2,3,4, William Kwon1,2,3,4, Junmei Wang1,2,3,4 & Xiang-Qun Xie1,2,3,4 Captagon, known by its genetic name Fenethylline, is an addictive drug that complicates the War on Drugs. Captagon has a strong CNS stimulating efect than its primary metabolite, Amphetamine. However, multi-targets issues associated with the drug and metabolites as well as its underlying mechanisms have not been fully defned. In the present work, we applied our established drug-abuse chemogenomics-knowledgebase systems pharmacology approach to conduct targets/of-targets mapping (SP-Targets) investigation of Captagon and its metabolites for hallucination addiction, and also analyzed the cell signaling pathways for both Amphetamine and Theophylline with data mining of available literature. Of note, Amphetamine, an agonist for trace amine-associated receptor 1 (TAAR1) with enhancing dopamine signaling (increase of irritability, aggression, etc.), is the main cause of Captagon addiction; Theophylline, an antagonist that blocks adenosine receptors (e.g. A2aR) in the brain responsible for restlessness and painlessness, may attenuate the behavioral sensitization caused by Amphetamine. We uncovered that Theophylline’s metabolism and elimination could be retarded due to competition and/or blockage of the CYP2D6 enzyme by Amphetamine; We also found that the synergies between these two metabolites cause Captagon’s psychoactive efects to act faster and far more potently than those of Amphetamine alone.
    [Show full text]